Literature DB >> 20558394

Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database.

Sid E O'Bryant1, Laura H Lacritz, James Hall, Stephen C Waring, Wenyaw Chan, Zeina G Khodr, Paul J Massman, Valerie Hobson, C Munro Cullum.   

Abstract

BACKGROUND: It was recently demonstrated that the Clinical Dementia Rating scale Sum of Boxes (CDR-SB) score can be used to accurately stage severity of Alzheimer dementia and mild cognitive impairment (MCI). However, to our knowledge, the utility of those interpretive guidelines has not been cross-validated or applied to a heterogeneous sample of dementia cases.
OBJECTIVE: To cross-validate the staging guidelines proposed in a previous study using the National Alzheimer's Coordinating Center (NACC) database.
DESIGN: The previously published cut scores were applied to the NACC sample and diagnostic accuracy estimates obtained. Next, analyses were restricted to NACC participants with a CDR global score (CDR-GS) of 0.5 and receiver operating characteristic curves generated to determine optimal CDR-SB cut scores for distinguishing MCI from very early dementia.
SETTING: The 2008 NACC uniform data set. PARTICIPANTS: There were 12 462 participants (5115 controls; 2551 patients with MCI; 4796 patients with dementia, all etiologies) in the NACC data set used for the current analysis. Main Outcome Measure Accurate prediction of diagnoses (MCI or dementia) using the CDR-SB score.
RESULTS: The previously proposed CDR-SB ranges successfully classified the vast majority of patients across all impairment ranges with a kappa of 0.91 and 94% overall correct classification rate. Additionally, the CDR-SB score discriminated between patients diagnosed with MCI and dementia when CDR-GS was restricted to 0.5 (overall area under the curve = 0.83).
CONCLUSIONS: These findings cross-validate the previously published CDR-SB interpretative guidelines for staging dementia severity and extend those findings to a large heterogeneous sample of patients with dementia. Additionally, the CDR-SB scores distinguished MCI from dementia in patients with reasonable accuracy when CDR-GS was restricted to 0.5.

Entities:  

Mesh:

Year:  2010        PMID: 20558394      PMCID: PMC2888493          DOI: 10.1001/archneurol.2010.115

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

1.  Estimating the predictive value of the Test of Memory Malingering: an illustrative example for clinicians.

Authors:  Sid E O'Bryant; John A Lucas
Journal:  Clin Neuropsychol       Date:  2006-09       Impact factor: 3.535

2.  Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study.

Authors:  Sid E O'Bryant; Stephen C Waring; C Munro Cullum; James Hall; Laura Lacritz; Paul J Massman; Philip J Lupo; Joan S Reisch; Rachelle Doody
Journal:  Arch Neurol       Date:  2008-08

3.  The clinical dementia rating sum of box score in mild dementia.

Authors:  C A Lynch; C Walsh; A Blanco; M Moran; R F Coen; J B Walsh; B A Lawlor
Journal:  Dement Geriatr Cogn Disord       Date:  2005-10-25       Impact factor: 2.959

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  A new clinical scale for the staging of dementia.

Authors:  C P Hughes; L Berg; W L Danziger; L A Coben; R L Martin
Journal:  Br J Psychiatry       Date:  1982-06       Impact factor: 9.319

6.  Implementing a screening and diagnosis program for dementia in primary care.

Authors:  Malaz Boustani; Christopher M Callahan; Frederick W Unverzagt; Mary G Austrom; Anthony J Perkins; Bridget A Fultz; Siu L Hui; Hugh C Hendrie
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

7.  2008 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

8.  Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment.

Authors:  L Berg; J P Miller; M Storandt; J Duchek; J C Morris; E H Rubin; W J Burke; L A Coben
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

  8 in total
  79 in total

1.  Antipsychotic Use in a Diverse Population With Dementia: A Retrospective Review of the National Alzheimer's Coordinating Center Database.

Authors:  Glen L Xiong; Teresa Filshtein; Laurel A Beckett; Ladson Hinton
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2015       Impact factor: 2.198

2.  Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.

Authors:  Ying Liu; Lan Tan; Hui-Fu Wang; Yong Liu; Xiao-Ke Hao; Chen-Chen Tan; Teng Jiang; Bing Liu; Dao-Qiang Zhang; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

3.  DEVELOPMENT OF CLINICAL DEMENTIA RATING SCALE CUTOFF SCORES FOR PATIENTS WITH PARKINSON'S DISEASE.

Authors:  Kathryn A Wyman-Chick; B J Scott
Journal:  Mov Disord Clin Pract       Date:  2015-04-20

4.  Impact of Alzheimer's disease on the family caregiver's long-term quality of life: results from an ALSOVA follow-up study.

Authors:  Tarja H Välimäki; Janne A Martikainen; Kristiina Hongisto; Saku Väätäinen; Harri Sintonen; Anne M Koivisto
Journal:  Qual Life Res       Date:  2015-09-09       Impact factor: 4.147

5.  Incident Antipsychotic Use in a Diverse Population with Dementia.

Authors:  Teresa Filshtein; Laurel A Beckett; Haley Godwin; Ladson Hinton; Glen L Xiong
Journal:  J Am Geriatr Soc       Date:  2016-07-19       Impact factor: 5.562

6.  The δ latent dementia phenotype in the uniform data set: Cross-validation and extension.

Authors:  Brandon E Gavett; Vanessa Vudy; Mary Jeffrey; Samantha E John; Ashita S Gurnani; Jason W Adams
Journal:  Neuropsychology       Date:  2014-08-25       Impact factor: 3.295

7.  Diagnostic accuracy and practice effects in the National Alzheimer's Coordinating Center Uniform Data Set neuropsychological battery.

Authors:  Melissa Mathews; Erin Abner; Richard Kryscio; Gregory Jicha; Gregory Cooper; Charles Smith; Allison Caban-Holt; Frederick A Schmitt
Journal:  Alzheimers Dement       Date:  2014-03-20       Impact factor: 21.566

8.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

10.  The link between C-reactive protein and Alzheimer's disease among Mexican Americans.

Authors:  Sid E O'Bryant; Leigh Johnson; Melissa Edwards; Holly Soares; Michael D Devous; Sarah Ross; Geoffrey Rohlfing; James Hall
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.